Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sezary Syndrome 1Sarcoma 1Paget Disease, Extramammary 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Mycosis Fungoides 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Eccrine Porocarcinoma 1Carcinoma, Signet Ring Cell 1Carcinoma, Merkel Cell 1Carcinoma, Basosquamous 1Carcinoma, Basal Cell 1Adenocarcinoma, Papillary 1

Interventions

Specimen Handling 3pembrolizumab 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Biopsy 2talimogene laherparepvec 1peposertib 1liposomal doxorubicin 1fludarabine 1aldesleukin 1X-Rays 1Radiotherapy 1Radiation 1Nivolumab 1Ipilimumab 1Histamine H2 Antagonists 1Famotidine 1Cyclophosphamide 1CTLA-4 Antigen 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × talimogene laherparepvec × 30 days × Clear all
NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡